Skip to main content
. 2016 Feb 8;23(2):71–79. doi: 10.3109/09286586.2015.1090004

Figure 1.

Figure 1.

Attrition of intravitreal anti-VEGF injection claims included for analysis of severe ocular inflammation rates in the US. nAMD, neovascular age-related macular degeneration; IDW, Integrated Data Warehouse; VEGF, vascular endothelial growth factor.Note: Injections were excluded if the administering physician exhibited evidence of “physician instability” (i.e. physicians with abnormally high or low prescribing patterns).